|
1 Company |
|
1 Product |
|
1 Product |
|
0 Mechanisms of Action |
|
0 Trials |
|
8 News |
|
- Phase classification: Porphozym in the Treatment of Acute Attacks in AIP (clinicaltrials.gov) - Mar 9, 2018
P2/3, N=36, Completed, Sponsor: Zymenex A/S
Phase classification: P2 --> P2/3
- Enrollment change, Trial withdrawal, Trial primary completion date: INHEPP;UTINH: Effect of Isoniazid on Protoporphyrin Levels in Erythropoietic Protoporphyria (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=0, Withdrawn, Sponsor: University of Utah
Phase classification: P2 --> P2/3 N=24 --> 0 | Enrolling by invitation --> Withdrawn | Trial primary completion date: Feb 2014 --> Dec 2015
- Trial completion, Gene therapy: Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria (clinicaltrials.gov) - Dec 19, 2014
P1, N=8, Completed, Sponsor: Digna Biotech S.L.
N=24 --> 0 | Enrolling by invitation --> Withdrawn | Trial primary completion date: Feb 2014 --> Dec 2015 Active, not recruiting --> Completed
- New P1 trial, Gene therapy: Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria (clinicaltrials.gov) - Mar 6, 2014
P1, N=8, Active, not recruiting, Sponsor: Digna Biotech S.L.
- Clinical: Observational Study of Acute Intermittent Porphyria Patients (clinicaltrials.gov) - Mar 2, 2014
P=N/A, N=9, Completed, Sponsor: Digna Biotech S.L.
- colestipol / Generic mfg.
Trial completion: Sorbent Therapy of the Cutaneous Porphyrias (clinicaltrials.gov) - Apr 28, 2013
P2/3, N=4, Completed, Sponsor: Brigham and Women's Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- deferasirox tablet for oral suspension / Generic mfg.
Trial completion: Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda (clinicaltrials.gov) - Sep 17, 2012
P3, N=10, Completed, Sponsor: University of Texas Southwestern Medical Center
Active, not recruiting --> Completed Recruiting --> Completed
- colestipol / Generic mfg.
New P2/3 trial: Sorbent Therapy of the Cutaneous Porphyrias (clinicaltrials.gov) - Aug 23, 2011
P2/3, N=4, Completed, Sponsor: Brigham and Women's Hospital